These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24724891)

  • 1. Differential diagnosis for a stable patient maintained on buprenorphine who gives a urine toxicology screen negative for buprenorphine.
    Sethi R; Petrakis I
    Am J Addict; 2014; 23(3):318-9. PubMed ID: 24724891
    [No Abstract]   [Full Text] [Related]  

  • 2. Urine Spiking in a Pain Medicine Clinic: An Attempt to Simulate Adherence.
    Lee D; Bazydlo LA; Reisfield GM; Goldberger BA
    Pain Med; 2015 Jul; 16(7):1449-51. PubMed ID: 25522892
    [No Abstract]   [Full Text] [Related]  

  • 3. Urine naloxone concentration at different phases of buprenorphine maintenance treatment.
    Heikman P; Häkkinen M; Gergov M; Ojanperä I
    Drug Test Anal; 2014 Mar; 6(3):220-5. PubMed ID: 23512803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of urinary naloxone levels in a single provider practice: a case study.
    Warrington JS; Booth K; Warrington GS; Francis-Fath S
    Addict Sci Clin Pract; 2020 Jan; 15(1):3. PubMed ID: 31941557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment.
    Suzuki J; Zinser J; Issa M; Rodriguez C
    Subst Abus; 2017; 38(4):504-507. PubMed ID: 28723256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine detection in urine using liquid chromatography-high-resolution mass spectrometry: comparison with cloned enzyme donor immunoassay (ThermoFisher) and homogeneous enzyme immunoassay (immunalysis).
    Belsey SL; Couchman L; Flanagan RJ
    J Anal Toxicol; 2014 Sep; 38(7):438-43. PubMed ID: 24925983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS.
    Marin SJ; McMillin GA
    Methods Mol Biol; 2016; 1383():69-78. PubMed ID: 26660175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of buprenorphine in urine].
    Hegstad S; Christophersen AS; Khiabani HZ
    Tidsskr Nor Laegeforen; 2008 Jan; 128(2):184-5. PubMed ID: 18202730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
    Häkkinen M; Heikman P; Ojanperä I
    Forensic Sci Int; 2013 Oct; 232(1-3):11-5. PubMed ID: 24053859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case 6-2019: A 29-Year-Old Woman with Nausea, Vomiting, and Diarrhea.
    Walley AY; Wakeman SE; Eng G
    N Engl J Med; 2019 Feb; 380(8):772-779. PubMed ID: 30786192
    [No Abstract]   [Full Text] [Related]  

  • 15. Buprenorphine detection in biological samples.
    De Giovanni N; Fucci N; Scarlata S; Donzelli G
    Clin Chem Lab Med; 2005; 43(12):1377-9. PubMed ID: 16309376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a fluoroimmunoassay for the detection of buprenorphine in urine.
    Debrabandere L; Van Boven M; Daenens P
    J Forensic Sci; 1995 Mar; 40(2):250-3. PubMed ID: 7602287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine and nor-buprenorphine levels in head hair samples from former heroin users under Suboxone® treatment.
    Belivanis S; Tzatzarakis MN; Vakonaki E; Kovatsi L; Mantsi M; Alegakis A; Kavvalakis MP; Vynias D; Tsatsakis AM
    Drug Test Anal; 2014 Jun; 6 Suppl 1():93-100. PubMed ID: 24817054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
    Holt SR; Donroe JH; Cavallo DA; Tetrault JM
    Drug Alcohol Depend; 2018 May; 186():171-174. PubMed ID: 29579725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.